Human umbilical cord mesenchymal stem cells ameliorate acute liver failure by inhibiting apoptosis, inflammation and pyroptosis.

Mengting Liu, Jing He, Shuo Zheng, Ke Zhang, Yu Ouyang, Yaqi Zhang, Changyong Li, Dongcheng Wu
Author Information
  1. Mengting Liu: Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.
  2. Jing He: Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.
  3. Shuo Zheng: R&D Center, Wuhan Hamilton Biotechnology Co., Ltd, Wuhan, China.
  4. Ke Zhang: Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.
  5. Yu Ouyang: Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.
  6. Yaqi Zhang: Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.
  7. Changyong Li: Department of Physiology, Wuhan University School of Basic Medical Sciences, Wuhan, China.
  8. Dongcheng Wu: Department of Biochemistry and Molecular Biology, Wuhan University School of Basic Medical Sciences, Wuhan, China.

Abstract

BACKGROUND: Human umbilical cord mesenchymal stem cells (UC-MSCs) are multipotent progenitor cells representing an attractive therapeutic tool for tissue damage and inflammation owing to their unique immunomodulatory properties. This study was designed to determine the protective effects and underlying mechanisms of UC-MSCs on acute liver failure (ALF).
METHODS: ALF was induced in mice by intraperitoneal injection of D-galactosamine (D-GalN) and lipopolysaccharide (LPS). Mice were intravenously injected with 1×10 UC-MSCs one hour before or six hours after D-GalN/LPS injection. Liver function was valued by serum biochemical parameters and hematoxylin-eosin staining. Inflammatory cytokine and chemokine levels were measured by real-time PCR, and inflammatory cells infiltration was observed by immunofluorescence staining. Hepatocyte apoptosis and pyroptosis related proteins were detected by western blot. Murine macrophage Raw264.7 in the presentation of LPS was treated with the UC-MSCs condition medium (UC-MSCs-CM), and then the levels of inflammatory cytokines and NOD-like receptor family pyrin domain containing 3 (NLRP3) inflammasome in Raw264.7 were measured.
RESULTS: UC-MSCs significantly reduced the mortality, decreased serum alanine aminotransferase and aspartate aminotransferase levels, and improved the pathological damage. Moreover, UC-MSCs inhibited inflammatory cytokine and chemokine levels, especially TNF-α, interleukins-6 (IL-6), IL-1β, monocyte chemoattractant protein (MCP-1), CC-chemokines ligand 2 (CCL2), C-X-C motif ligand 2 (CXCL2), and reduced macrophage, neutrophil and T lymphocyte infiltration into the liver tissue. UC-MSCs also attenuated hepatocyte apoptosis, as evidenced by decreased TUNEL positive cells, increased Bcl-xl/Bax protein ratio and downregulated cleaved caspase 3 levels. NLRP3 inflammasome activation, IL-1β maturation and cleaved caspase1 were suppressed by UC-MSC administration. Furthermore, the UC-MSCs-CM reduced the levels of inflammatory cytokines and the activation of NLRP3 inflammasome in Raw264.7.
CONCLUSIONS: Our results demonstrated that UC-MSCs exerted therapeutic effects on ALF by inhibiting apoptosis, inflammation, and pyroptosis.

Keywords

References

  1. Stem Cell Res Ther. 2020 Sep 3;11(1):377 [PMID: 32883343]
  2. Hepatology. 2000 Oct;32(4 Pt 1):734-9 [PMID: 11003617]
  3. Stem Cell Rev Rep. 2013 Apr;9(2):226-40 [PMID: 23233233]
  4. Cells. 2020 Jun 22;9(6): [PMID: 32580448]
  5. Stem Cell Res Ther. 2015 Mar 21;6:40 [PMID: 25890008]
  6. Clin Liver Dis. 2018 May;22(2):419-427 [PMID: 29605076]
  7. Cell Stem Cell. 2012 Jun 14;10(6):709-716 [PMID: 22704511]
  8. Immunity. 2009 Jan 16;30(1):56-66 [PMID: 19119023]
  9. Nat Rev Gastroenterol Hepatol. 2018 Dec;15(12):738-752 [PMID: 30250076]
  10. Nat Immunol. 2014 Aug;15(8):738-48 [PMID: 24952504]
  11. Gastroenterology. 2018 Jan;154(1):46-56 [PMID: 29107021]
  12. J Gastroenterol Hepatol. 2012 Mar;27 Suppl 2:112-20 [PMID: 22320928]
  13. Front Immunol. 2018 Dec 14;9:2948 [PMID: 30619308]
  14. Stem Cells. 2014 Nov;32(11):2818-23 [PMID: 25154380]
  15. Stem Cell Res Ther. 2018 Mar 21;9(1):72 [PMID: 29562935]
  16. J Transl Med. 2016 Feb 09;14:45 [PMID: 26861623]
  17. J Hepatol. 2018 May;68(5):986-995 [PMID: 29366909]
  18. Cell Death Dis. 2016 Sep 29;7(9):e2391 [PMID: 27685635]
  19. Stem Cell Res Ther. 2020 Aug 3;11(1):336 [PMID: 32746936]
  20. Cell Death Differ. 2020 Feb;27(2):466-481 [PMID: 31209359]
  21. Int J Mol Med. 2016 Mar;37(3):773-80 [PMID: 26865215]
  22. Ann Transl Med. 2019 Aug;7(16):392 [PMID: 31555706]
  23. J Hepatol. 2018 Apr;68(4):773-782 [PMID: 29273476]
  24. Immunol Rev. 2015 May;265(1):143-55 [PMID: 25879290]
  25. J Hepatol. 2015 Apr;62(1 Suppl):S112-20 [PMID: 25920080]
  26. Hepatology. 2019 Nov;70(5):1714-1731 [PMID: 31063235]
  27. J Transl Med. 2012 Jun 26;10:133 [PMID: 22735033]
  28. Hepatobiliary Pancreat Dis Int. 2016 Dec;15(6):602-611 [PMID: 27919849]
  29. J Hepatol. 2017 Apr;66(4):836-848 [PMID: 27913221]
  30. Stem Cells Int. 2018 Jul 12;2018:9156560 [PMID: 30123296]
  31. J Hepatol. 2021 Jan;74(1):156-167 [PMID: 32763266]
  32. Gut. 2012 Jun;61(6):894-906 [PMID: 21997562]
  33. Am J Physiol Renal Physiol. 2020 Jan 1;318(1):F96-F106 [PMID: 31682173]
  34. Eur J Pharmacol. 2018 Jan 15;819:161-168 [PMID: 29191769]

Word Cloud

Created with Highcharts 10.0.0UC-MSCscellslevelsapoptosisliverALFinflammatorypyroptosisinflammasomecordmesenchymalsteminflammationacutefailureRaw2647NLRP3reducedHumanumbilicaltherapeutictissuedamageeffectsinjectionLPSserumstainingcytokinechemokinemeasuredinfiltrationmacrophageUC-MSCs-CMcytokines3decreasedaminotransferaseIL-1βproteinligand2cleavedactivationinhibitingBACKGROUND:multipotentprogenitorrepresentingattractivetoolowinguniqueimmunomodulatorypropertiesstudydesigneddetermineprotectiveunderlyingmechanismsMETHODS:inducedmiceintraperitonealD-galactosamineD-GalNlipopolysaccharideMiceintravenouslyinjected1×10onehoursixhoursD-GalN/LPSLiverfunctionvaluedbiochemicalparametershematoxylin-eosinInflammatoryreal-timePCRobservedimmunofluorescenceHepatocyterelatedproteinsdetectedwesternblotMurinepresentationtreatedconditionmediumNOD-likereceptorfamilypyrindomaincontainingRESULTS:significantlymortalityalanineaspartateimprovedpathologicalMoreoverinhibitedespeciallyTNF-αinterleukins-6IL-6monocytechemoattractantMCP-1CC-chemokinesCCL2C-X-CmotifCXCL2neutrophilTlymphocytealsoattenuatedhepatocyteevidencedTUNELpositiveincreasedBcl-xl/Baxratiodownregulatedcaspasematurationcaspase1suppressedUC-MSCadministrationFurthermoreCONCLUSIONS:resultsdemonstratedexertedameliorateUmbilical

Similar Articles

Cited By